(Q33236875)

24 July 2017

1 reference

title

Extended-spectrum beta-lactamases and clinical outcomes: current data (English)

1 reference

24 July 2017

2

Paul G Ambrose

1 reference

24 July 2017

Reuben Ramphal

1

1 reference

PubMed ID

16544267

24 July 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

Clinical Infectious Diseases

24 July 2017

1 reference

24 July 2017

42 Suppl 4

1 reference

24 July 2017

S164-72

1 reference

Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs).

24 July 2017

1 reference

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

21 January 2018

1 reference

Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime

21 January 2018

1 reference

Therapeutic challenges associated with extended-spectrum, beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae

21 January 2018

1 reference

Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome

21 January 2018

1 reference

Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia

21 January 2018

1 reference

Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome

21 January 2018

1 reference

Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes

21 January 2018

1 reference

Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility

21 January 2018

1 reference

Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum beta-lactamase

21 January 2018

1 reference

Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae

21 January 2018

1 reference

CTX-M-14, a plasmid-mediated CTX-M type extended-spectrum beta-lactamase isolated from Escherichia coli

21 January 2018

1 reference

TEM-71, a novel plasmid-encoded, extended-spectrum beta-lactamase produced by a clinical isolate of Klebsiella pneumoniae

21 January 2018

1 reference

Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae

21 January 2018

1 reference

Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center

21 January 2018

1 reference

The inoculum effect: fact or artifact?

21 January 2018

1 reference

Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula

21 January 2018

1 reference

Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins

21 January 2018

1 reference

MYSTIC program: summary of European data from 1997 to 2000.

21 January 2018

1 reference

Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000)

21 January 2018

1 reference

Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme

21 January 2018

1 reference

Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA).

21 January 2018

1 reference

Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I--results from the SENTRY Antimicrobial Surveillance Program (North America, 1998).

21 January 2018

1 reference

Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.

21 January 2018

1 reference

Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe

21 January 2018

1 reference

Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region

21 January 2018

1 reference

In vitro and in vivo activities of ciprofloxacin and levofloxacin against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain

21 January 2018

1 reference

Activity of levofloxacin and ciprofloxacin against urinary pathogens

21 January 2018

1 reference

Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.

21 January 2018

1 reference

Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs

21 January 2018

1 reference

Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99).

21 January 2018

1 reference

Molecular epidemiology of extended-spectrum beta-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan

21 January 2018

1 reference

Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection

21 January 2018

1 reference

Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae

21 January 2018

1 reference

Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000).

21 January 2018

1 reference

Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime

21 January 2018

1 reference

Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases: Report from the ARREST Program

21 January 2018

1 reference

Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study

21 January 2018

1 reference

The effect of an antimicrobial formulary change on hospital resistance patterns

21 January 2018

1 reference

Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella

21 January 2018

1 reference

Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/500663

1 reference

24 July 2017

1 reference

PubMed ID

16544267